

CHIEF PHARMACEUTICAL INSPECTORATE

[the national emblem of the Republic of Poland]---
Chief Pharmaceutical Inspector

Done at Warsaw on 16 April 2019---

Reference: **NMO.5520.8.2019.MEK.2---**

LICENCE

Pursuant to Articles 40.1 and 39.3 of the Drug Addiction Counteracting Act of 29 July 2005 (Journal of Laws – year 2018, item 1030, as amended), the Regulation of the Minister of Health of 17 August 2018 on the list of psychotropic substances, narcotic drugs and new psychoactive substances (Journal of Laws - year 2018, item 1591) and Articles 104.1 and 104.2 of the Code of Administrative Procedure of 14 June 1960 (Journal of Laws – year 2018, item 2096),---

THE CHIEF PHARMACEUTICAL INSPECTOR

having considered the Application of the following entrepreneur:---

SWISSCARE PHARMA SP. Z O.O. SP. K. [*limited partnership under the Polish Law*]
with the registered office in Elbląg, Poland,


hereby grants

a licence for wholesale trade in the narcotic drugs of Groups I-N, II-N, III-N and psychotropic substances of Groups II-P, III-P and IV-P at the Wholesale Store located in Łódź at 100/102 Rzgowska street, operating pursuant to Licence no. NOH.5100.66.2018.1124.MG.4 granted by the Chief Pharmaceutical Inspector on 9 October 2018---

The commencement and running of the activities must be in compliance with the Drug Addiction Counteracting Act (J/L - year 2018, item 1030, as amended) and the provisions on medicinal products and medical devices, including, in particular, narcotic drugs and psychotropic substances and the supervision of these drugs and substances.---

Grounds

Pursuant to Article 107.4 of the Code of Administrative Procedure, the Chief Pharmaceutical Inspector shall refrain from justifying the decision as long as all of the Applicant's requests have been granted.---



Certified Translation from the Polish Language

Pursuant to Article 127.3 of the Code of Administrative Procedure of 14 June 1960 (hereinafter referred to as CAP) this decision is unappealable, however, the Applicant may apply to the Chief Pharmaceutical Inspector for a review of the request within 14 days of the receipt of this Decision.---

Further, pursuant to Article 52.3 of the Act of 30 August 2002 - Law on Proceedings before Administrative Courts, a party may file a complaint against this Decision without first availing of the right to request review; the complaint should be filed with the Province Administrative Court in Warsaw, through the agency of the Chief Pharmaceutical Inspector, within 30 days of the receipt of this Decision. The application fee for a complaint is PLN 3000. A party may apply for exemption from court costs and a grant of legal assistance as prescribed in the Law on Proceedings before Administrative Courts (Articles 239-262).---

In accordance with Article 127a.1 of the Code of Administrative Procedure, before the deadline for filing for a review of the case expires, the party may waive the right to request a review before the authority that issued the Decision. The decision becomes final and valid on the day the public administration body has received the statement of waiver of the right to file a request for review.---

[stamp:] 'On behalf of Chief Pharmaceutical Inspector – Joanna Szajnik-Solska – Supervision Department Director'---

(-) [signed]---

[a round seal with the national emblem of the Republic of Poland and the following inscription: 'Główny Inspektor Farmaceutyczny' /Chief Pharmaceutical Inspector/]---

Recipients:---

1. Applicant: Swisscare Pharma Sp. z o.o. sp. k., ul. Jarosława Iwaszkiewicza 37, 82-300 Elbląg, Poland, represented by Mr Adam Kliś, LLM, ul. Berensona 157 D, 03-287 Warsaw, Poland---
2. case files---

I hereby certify that this is a true and correct translation of the original document in the Polish language.

Translator's Register entry no. 530/2019

Elbląg, 30 April 2019

BIURO TŁUMACZEŃ RK
mgr Rafał Korzeniewski
82-300 Elbląg, Oboźna 19/19A
tel. 55 629 33 05, kom. 666 577 193
biuro@tlumaczenia.elblag.pl
REGON 171012594, NIP 578-212-81-70

